news

Study reveals how to make pancreatic cancer chemotherapy more effective

Researchers have shown that blocking a particular enzyme causes chemotherapy to become more effective against pancreatic cancers in pre-clinical studies.

Researchers have uncovered a promising new pathway to combat pancreatic adenocarcinoma (PDAC) resistance to chemotherapy.

The study, conducted by the Mayo Clinic, US, revealed that the inhibition of an enzyme involved in many cancer-promoting processes sensitises PDAC cell lines to gemcitabine, the most commonly used cancer therapy.

Using patient cell lines and tumour-bearing models, the team blocked the GSK-3 enzyme using a new inhibitor called 9-ING-41, alone or with chemotherapy. They found it prevented cancer cells’ ability to repair single-strand DNA damage induced by the chemotherapy.

 

Reserve your FREE place

 


Are you advancing promising antibody leads, only to encounter issues with stability, PK or manufacturability later in development?

30 July 2025 | 10:00 AM BST | FREE Webinar

Join us for an expert-led webinar exploring how early-stage developability assessment can help reduce downstream risk and improve candidate selection.

What You’ll Learn:

  • How to identify key developability risks early including aggregation, PK, and manufacturability
  • How to implement high-throughput in vitro assays requiring <1 mg of antibody per test
  • How to combine in silico modeling with wet-lab analytics to guide early optimisation

Don’t miss your chance to learn from Dr Lei Guo.

Register Now – It’s Free!

 

…the GSK-3 inhibitor significantly increased pancreatic tumour cancer cell death and prolonged survival”

“Our study identified a previously unknown role for GSK-3 in the regulation of the cell’s ability to respond to and repair its DNA following chemotherapy,” says Dr Daniel Billadeau, professor of immunology, biochemistry and molecular biology at Mayo Clinic College of Medicine and Science. “The findings suggest that by inhibiting GSK-3, we can impede the cells’ DNA damage response, leading to synergistic tumour cell death even in cells that are naturally resistant to chemotherapy.”

The researchers found that the GSK-3 inhibitor significantly increased pancreatic tumour cancer cell death and prolonged survival of the tumour-bearing models.

“Many pancreatic cancer tumours are resistant to the two most commonly used chemotherapies,” says Dr Li Ding, a Mayo Clinic senior research fellow and the study’s lead author. “Thus, identifying ways in which to make resistant tumours sensitive, or to increase the effectiveness of chemotherapy, is vital.”

The results were published in Clinical Cancer Research.

Leave a Reply

Your email address will not be published. Required fields are marked *